Last edition
News about Biotechnology
Aurobindo Pharma Wins UK MHRA Approval for Dazublys Trastuzumab Biosimilar
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys, used in the treatment of HER2-positive breast and gastric cancers.
Biotechnology | 27/08/2025 | By Darshana | 346
This marks the third collaboration BioArctic has entered into with partners using the BrainTransporter technology.
Biotechnology | 27/08/2025 | By Dineshwori | 560
Novartis Expands Collaboration with BioArctic, Eyes Licensing Opportunity Worth Up to $772 Million
The partnership focuses on combining BioArctic’s BrainTransporter technology with a Novartis proprietary antibody to develop a novel drug candidate. Should Novartis proceed, it would take full responsibility for the candidate’s global development and commercialization.
Biotechnology | 26/08/2025 | By Darshana | 427
Collaboration Aims to Scale AAV Manufacturing for Rare Neuromuscular Junction Diseases
NMJ disorders often cause severe muscle weakness, with many patients requiring respiratory support, wheelchairs, or tube feeding. These genetic diseases can be life-threatening, often diagnosed in childhood but sometimes appearing later in life.
Biotechnology | 24/08/2025 | By Darshana | 164
Gilead's Kite Acquires Interius BioTherapeutics for USD 350 Million to Fuel In Vivo CAR-T Innovation
Gilead Sciences’ subsidiary Kite Pharma has announced the acquisition of Interius BioTherapeutics, a privately held biotech company, for USD 350 million in cash. The deal is aimed at advancing Kite’s development of in vivo CAR-T cell therapies, considered a next-generation approach to cancer treatment.
Biotechnology | 22/08/2025 | By Darshana | 350
AnGes and Boehringer Ingelheim Advance PAD Gene Therapy with New Manufacturing Deal
Boehringer Ingelheim has signed a contract development and manufacturing agreement with AnGes Inc. for the drug substance of AnGes’ investigational therapy for peripheral arterial disease (PAD). This agreement marks a key step following AnGes’ recent completion of clinical trials and its plan to submit a biologics license application (BLA).
Biotechnology | 21/08/2025 | By Darshana | 379
Sun Pharma Recalls Over 11,000 Bottles of Blood-Pressure Drug in US Over Contamination
Sun Pharmaceutical Industries Inc’s US subsidiary has voluntarily recalled 11,328 bottles of Spironolactone tablets after traces of aluminium contamination were discovered.
Biotechnology | 16/08/2025 | By Darshana | 788
The minister also laid the foundation stone for a new hostel block and Type-IV quarters at NIAB, sanctioned by the Department of Biotechnology (DBT) at a cost of INR 19.98 crore. This infrastructure aims to support research scholars, faculty and staff, fostering a dynamic environment for innovation and academic growth.
Biotechnology | 12/08/2025 | By Darshana | 673
Over INR 4,894 Crore Allocated for Bio-Incubators Since 2012: Govt
A total of 94 biotechnology incubation and pre-incubation centres have been set up across 25 States and Union Territories under BioNEST and E-YUVA schemes.
Biotechnology | 31/07/2025 | By Dineshwori | 341
Nepexto Debuts in Australia as Biocon Biologics Expands Biosimilar Presence Globally
Biocon Biologics Ltd (BBL), a global biosimilars company and subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has announced the launch of Nepexto®, a biosimilar of Enbrel® (Etanercept), in Australia.
Biotechnology | 24/07/2025 | By Darshana | 251
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy